Statistical data support prediction of death within 6 months on low levels of coenzyme Q10 and other entities.
Ninety-four consecutive hospital patients aged over 50 years were included in a cross-sectional study. Serum samples were analyzed for coenzyme Q10, alpha-tocopherol, and free cholesterol levels. Patients who died within a follow-up period of 6 months or had congestive heart failure or severe myalgia, and/or received cytostatic or lipid-lowering drug therapy showed significantly lower free cholesterol-related coenzyme Q10 values. Prospective controlled clinical trials will determine whether coenzyme Q10 has a potential to protect patients from such complications and become a useful therapy.
Jameson
S
S
Department of Internal Medicine, Samariterhemmet Hospital, Uppsala.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002784:Cholesterol / Q000097:blood*; D003067:Coenzymes; D003430:Cross-Sectional Studies; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D015996:Survival Rate; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood; D014810:Vitamin E / Q000097:blood*
D003067:Coenzymes; D014451:Ubiquinone; D014810:Vitamin E; D002784:Cholesterol; C024989:coenzyme Q10